Azacitidine

From Ganfyd

Jump to: navigation, search

Contents

Introduction

Analogue of the nucleoside cytidine. Originally developed as a chemotherapeutic drug for cancer, it is licensed for use for treatment of myelodysplastic syndrome. Its effects may be mediated by two mechanisms: firstly, a direct cytotoxicity through incorporation of the drug into RNA/DNA synthesis, and secondly, inhibition of DNA methyltransferase, resulting in hypomethylation of previously epigenetically suppressed genes.

Clinical Use

Indications

Refractory myelodysplasia[1] (EU licensing expected 2008, Licensed since 2005 USA)

Administration

IV

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

Include[2]:

Special advice

Pharmacology

DNA methyltransferase inhibitor

References

This article is a work in progress. Please feel free to contribute to it.